NCT00995995View on ClinicalTrials.gov

Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK

CompletedOBSERVATIONAL

Enrollment

7,641

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

January 31, 2009

Study Completion Date

February 28, 2009

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Rosiglitazone

Rosiglitazone

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00995995 - Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK | Biotech Hunter | Biotech Hunter